Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
复制标题
DOI：
10.1111/j.1360-0443.2010.03170.x
复制
发表时间：
2011-03
期刊：
影响因子：
--
通讯作者：
Ehrlich ME
中科院分区：
文献类型：
--
作者：
Kraft WK;Dysart K;Greenspan JS;Gibson E;Kaltenbach K;Ehrlich ME
Over half of infants exposed to opioids in utero develop neonatal abstinence syndrome (NAS) of severity to require pharmacologic therapy. Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS. Randomized, phase 1, open-label, active-control clinical trial comparing sublingual buprenorphine to oral morphine. Large, urban, tertiary care hospital. Twenty-four term infants requiring pharmacological treatment for NAS. Outcomes were neonatal safety, length of treatment, and length of hospitalization. Sublingual buprenorphine was safe and effective. Infants treated with buprenorphine had a 23-day length of treatment compared to 38 days for those treated with morphine (p=0.01), representing a 40% reduction. Length of hospital stay in the buprenorphine group was reduced 24%, from 42 to 32 days (p=0.05). Sublingual buprenorphine was safe in NAS, with a substantial efficacy advantage over standard of care therapy with oral morphine.
登录
查看更多内容
影响因子：
1.7
作者：
Oei, J;Feller, JM;Lui, K
通讯作者：
Lui, K
影响因子：
5.1
作者：
Coyle, MG;Ferguson, A;Lester, B
通讯作者：
Lester, B
影响因子：
1.6
作者：
Crocetti, Michael T.;Amin, Diane D.;Jansson, Lauren M.
通讯作者：
Jansson, Lauren M.
影响因子：
1
作者：
Blaeser, A.;Pulzer, F.;Kiess, W.
通讯作者：
Kiess, W.
影响因子：
8
作者：
Kraft WK;Gibson E;Dysart K;Damle VS;Larusso JL;Greenspan JS;Moody DE;Kaltenbach K;Ehrlich ME
通讯作者：
Ehrlich ME